Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Beth Psaila, who has won a prestigious Fellowship at the L’Oréal-UNESCO UK and Ireland For Women In Science awards. She was one of five scientists to receive the highly competitive award.

Beth (second from right) with other winners and Prof Dame Carol Robinson

The annual Fellowships programme provides £15,000 of flexible financial support for outstanding female postdoctoral researchers to continue research in their fields, as part of a wider L’Oréal-UNESCO programme aimed at supporting and increasing the number of women working in STEM professions in the UK, where 85% of jobs are held by men.

Dr Beth Psaila (WIMM-NDCLS) is a haematologist examining the role of blood cells in the bone marrow, known as megakaryocytes, in a rare but fatal disease called Myelofibrosis which destroys the bone marrow. Most patients live for fewer than five years after diagnosis, and 20% develop blood cancer. Current treatments help symptoms but do not cure the condition or improve survival. The condition is triggered by a mutation in a key gene called JAK2, and better understanding how the disease develops at a genetic level could help in the design of new treatments.

Read more ....

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

Clinical Trials Coronavirus COVID-19 General Research

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19.